Join us on November 29 at 1 PM for a virtual webinar to hear about the 1st of its kind, ARPA-H application process from our LabCentral resident awardee Stan Wang and grant guru and alumni Laura Hales. We are pleased to host this Q&A informative session online for our community so bring your questions!
About ARPA-H
ARPA-H investments are supporting the development of high impact solutions to most challenging health problems with the goal of transforming important areas of medicine and health that cannot readily be accomplished through traditional research or commercial activity. Since it is established in 2022, They opened up submissions for their 1st BAA (Broad Agency Announcement) that is on a rolling basis until March 2024. They have funded 7 projects as of October 2023. Focus areas illustrate the types of work and impact that ARPA-H pursues and hires the 1st Program Managers who are framing a challenge and awards projects to teams.
SESSION SPEAKERS
SESSION SPEAKERS
Stan Wang, MBA, PhD
Founder & CEO
Thymunne Therapeutics
Stan Wang is Founder and CEO of Thymmune Therapeutics, an innovative cell therapy company working to address high unmet needs across immunology. Previously, Stan was Founding Chief Scientific Officer at Cellino Biotech, where he led R&D and application of its technology to rapidly engineer cells. Stan received his Ph.D. from the University of Cambridge and his M.D. from Columbia University. He was a postdoctoral fellow in cell and gene therapy with George Church at Harvard Medical School.
Laura Hales, PhD
Co-founder & CBO
Extend Biosciences
Stan Wang is Founder and CEO of Thymmune Therapeutics, an innovative cell therapy company working to address high unmet needs across immunology. Previously, Stan was Founding Chief Scientific Officer at Cellino Biotech, where he led R&D and application of its technology to rapidly engineer cells. Stan received his Ph.D. from the University of Cambridge and his M.D. from Columbia University. He was a postdoctoral fellow in cell and gene therapy with George Church at Harvard Medical School.
Laura is a PhD scientist and Founder and Principal of The Isis Group, a scientific communications company specializing in obtaining government grants and other non-dilutive funding for life sciences companies. She is also a Cofounder of Extend Biosciences, a clinical-stage biotechnology company with a novel drug delivery platform D-VITylation(TM) that harnesses the biology of vitamin D to extend the half-life and improve the subcutaneous bioavailability of therapeutic peptides. The company is a LabCentral alum, and has raised >$18M in non-dilutive funding to build the D-VITylation platform, and their lead program, a long-acting PTH, is currently entering Phase 2 clinical trials for the rare disease hypoparathyroidism.